Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

ulipristal acetate 20Uterine Myomectomy 19telapristone acetate 18vilaprisan 12relugolix 12Leuprolide 11Uterine Artery Embolization 10estradiol, norethindrone drug combination 9asoprisnil 9Estradiol 8elagolix 7Tranexamic Acid 7Mifepristone 7Bupivacaine 7ulipristal 6Norethindrone Acetate 6Hysterectomy 6Saline Solution 5linzagolix 4epigallocatechin gallate 4Sodium Chloride 4Misoprostol 4Letrozole 4Vitamin B 6 3Tablets 3Surveys and Questionnaires 3Sugars 3Radiofrequency Ablation 3Lidocaine 3Hysteroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyoma × Medroxyprogesterone Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡